Mateon Therapeutics Company Profile (NASDAQ:MATN)

About Mateon Therapeutics (NASDAQ:MATN)

Mateon Therapeutics logoMateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MATN
  • CUSIP: N/A
  • Web: www.mateon.com/
Capitalization:
  • Market Cap: $7.16 million
  • Outstanding Shares: 26,544,000
Average Prices:
  • 50 Day Moving Avg: $0.39
  • 200 Day Moving Avg: $0.47
  • 52 Week Range: $0.16 - $0.89
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.59
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.19 per share
  • Price / Book: 1.41
Profitability:
  • EBITDA: ($14,590,000.00)
  • Return on Equity: -224.38%
  • Return on Assets: -186.53%
Debt:
  • Current Ratio: 11.63%
  • Quick Ratio: 11.63%
Misc:
  • Average Volume: 73,656 shs.
  • Beta: 1.53
  • Short Ratio: 8.04
 

Frequently Asked Questions for Mateon Therapeutics (NASDAQ:MATN)

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the NASDAQ under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (NASDAQ:MATN) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.03. View Mateon Therapeutics' Earnings History.

Where is Mateon Therapeutics' stock going? Where will Mateon Therapeutics' stock price be in 2017?

4 equities research analysts have issued 12 month price objectives for Mateon Therapeutics' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Mateon Therapeutics' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Mateon Therapeutics.

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:

  • William D. Schwieterman M.D., Chairman of the Board, President, Chief Executive Officer
  • Matthew M. Loar CPA, Chief Financial Officer, Principal Accounting Officer
  • David Chaplin Ph.D., Chief Scientific Officer, Director
  • Simon C Pedder Ph.D., Director
  • Donald R. Reynolds, Independent Director
  • Bobby W. Sandage Jr., Ph.D., Independent Director

How do I buy Mateon Therapeutics stock?

Shares of Mateon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of Mateon Therapeutics stock can currently be purchased for approximately $0.27.


MarketBeat Community Rating for Mateon Therapeutics (NASDAQ MATN)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mateon Therapeutics (NASDAQ:MATN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $2.00 (641.02% upside)
Consensus Price Target History for Mateon Therapeutics (NASDAQ:MATN)
Price Target History for Mateon Therapeutics (NASDAQ:MATN)
Analysts' Ratings History for Mateon Therapeutics (NASDAQ:MATN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/1/2017Maxim GroupReiterated RatingHoldHighView Rating Details
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$2.00MediumView Rating Details
3/13/2017HC WainwrightInitiated CoverageBuy$2.00HighView Rating Details
3/13/2017Rodman & RenshawReiterated RatingBuy -> Buy$2.00HighView Rating Details
1/29/2016S&P Equity ResearchLower Price Target$0.64 -> $0.58N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Mateon Therapeutics (NASDAQ:MATN)
Earnings by Quarter for Mateon Therapeutics (NASDAQ:MATN)
Earnings History by Quarter for Mateon Therapeutics (NASDAQ MATN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.12)($0.15)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.13)($0.15)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.13)($0.13)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.15)($0.12)ViewN/AView Earnings Details
5/9/2016Q116($0.19)($0.13)ViewN/AView Earnings Details
11/10/2015Q3($0.13)($0.14)ViewN/AView Earnings Details
8/4/2015Q215($0.10)($0.13)ViewN/AView Earnings Details
4/30/2015Q115($0.13)($0.13)ViewN/AView Earnings Details
4/14/2015($0.13)($0.11)ViewN/AView Earnings Details
3/17/2015Q414($0.17)($0.11)ViewN/AView Earnings Details
11/12/2014Q3($0.23)($0.17)ViewListenView Earnings Details
8/5/2014Q2 2014($0.13)($0.23)ViewN/AView Earnings Details
5/6/2014Q1 2014($0.19)($0.29)ViewN/AView Earnings Details
3/18/2014Q412($4.67)ViewN/AView Earnings Details
11/12/2013Q3($1.88)ViewListenView Earnings Details
11/8/2012Q312($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mateon Therapeutics (NASDAQ:MATN)
Current Year EPS Consensus Estimate: $-0.4200 EPS
Next Year EPS Consensus Estimate: $-0.4600 EPS

Dividends

Dividend History for Mateon Therapeutics (NASDAQ:MATN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mateon Therapeutics (NASDAQ:MATN)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 8.60%
Insider Trades by Quarter for Mateon Therapeutics (NASDAQ:MATN)
Insider Trades by Quarter for Mateon Therapeutics (NASDAQ:MATN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2016Donald Rogers ReynoldsDirectorBuy30,000$0.35$10,500.00View SEC Filing  
6/28/2013Peter LangeckerCEOBuy3,000$2.75$8,250.00View SEC Filing  
6/25/2013Peter LangeckerCEOBuy2,000$2.79$5,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Mateon Therapeutics (NASDAQ:MATN)
Latest Headlines for Mateon Therapeutics (NASDAQ:MATN)
Source:
DateHeadline
americanbankingnews.com logo-$0.11 Earnings Per Share Expected for Mateon Therapeutics Inc (MATN) This Quarter
www.americanbankingnews.com - October 13 at 12:24 AM
americanbankingnews.com logoHead-To-Head Contrast: Mateon Therapeutics (MATN) vs. Its Competitors
www.americanbankingnews.com - October 5 at 6:26 AM
americanbankingnews.com logoFinancial Review: Mateon Therapeutics (MATN) and Its Competitors
www.americanbankingnews.com - October 2 at 8:14 PM
nasdaq.com logoAKBA Hits New 52-week High, PMD Launches Hair Test, Mateon Runs Out Of FOCUS - Nasdaq
www.nasdaq.com - September 27 at 9:52 AM
globenewswire.com logoMateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize ... - GlobeNewswire (press release)
globenewswire.com - September 27 at 9:52 AM
finance.yahoo.com logoMateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
finance.yahoo.com - September 27 at 9:52 AM
americanbankingnews.com logoMateon Therapeutics (MATN) and Its Rivals Critical Contrast
www.americanbankingnews.com - September 14 at 12:24 PM
seekingalpha.com logoMateon Therapeutics (MATN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 7:28 AM
finance.yahoo.com logoMateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017
finance.yahoo.com - September 7 at 12:56 AM
americanbankingnews.com logoMateon Therapeutics Inc (MATN) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - August 18 at 2:14 AM
globenewswire.com logoMateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum ... - GlobeNewswire (press release)
globenewswire.com - August 17 at 1:44 AM
finance.yahoo.com logoMateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
finance.yahoo.com - August 17 at 1:44 AM
finance.yahoo.com logoMateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:17 AM
finance.yahoo.com logoMateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer
finance.yahoo.com - August 2 at 3:39 AM
americanbankingnews.com logoMateon Therapeutics Inc (NASDAQ:MATN) Given "Hold" Rating at Maxim Group
www.americanbankingnews.com - August 1 at 3:22 PM
seekingalpha.com logoMateon's OXi4503 shows positive treatment effect in early-stage study - Seeking Alpha
seekingalpha.com - July 31 at 8:01 PM
globenewswire.com logoMateon Therapeutics Announces Positive Initial Data from Fifth ... - GlobeNewswire (press release)
globenewswire.com - July 31 at 8:01 PM
finance.yahoo.com logoMateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
finance.yahoo.com - July 31 at 8:01 PM
americanbankingnews.com logoMateon Therapeutics (NASDAQ:MATN) and Osiris Therapeutics (OSIR) Head to Head Review
www.americanbankingnews.com - July 30 at 8:22 PM
americanbankingnews.com logoFinancial Review: Affymax (AFFY) versus Mateon Therapeutics (NASDAQ:MATN)
www.americanbankingnews.com - July 27 at 12:54 PM
americanbankingnews.com logoContrasting Mateon Therapeutics (NASDAQ:MATN) & Affymax (AFFY)
www.americanbankingnews.com - July 22 at 8:03 AM
americanbankingnews.com logo-$0.13 Earnings Per Share Expected for Mateon Therapeutics Inc (MATN) This Quarter
www.americanbankingnews.com - July 6 at 6:20 PM
globenewswire.com logoMateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors
globenewswire.com - June 28 at 8:04 PM
streetinsider.com logoMateon Therapeutics (MATN) Reports New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors - StreetInsider.com
www.streetinsider.com - June 28 at 7:55 AM
nasdaq.com logoMateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones - Nasdaq
www.nasdaq.com - June 12 at 9:27 AM
seekingalpha.com logoMateon's OXi4503 Fast Track'd for AML; shares ahead 18% - Seeking Alpha
seekingalpha.com - June 8 at 10:19 AM
globenewswire.com logoMateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
globenewswire.com - April 18 at 5:50 PM
globenewswire.com logoMateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 30 at 11:44 PM
nasdaq.com logoHealth Care Sector Update for 03/15/2017: MATN - Nasdaq
www.nasdaq.com - March 15 at 6:39 PM
globenewswire.com logoMateon Therapeutics to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 8 at 7:11 PM
us.rd.yahoo.com logoMateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
us.rd.yahoo.com - February 13 at 7:31 PM
biz.yahoo.com logoMATEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
biz.yahoo.com - January 13 at 7:41 PM
biz.yahoo.com logoMATEON THERAPEUTICS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and E
biz.yahoo.com - December 15 at 7:04 PM
us.rd.yahoo.com logoMateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology
us.rd.yahoo.com - December 6 at 10:01 AM
us.rd.yahoo.com logo7:04 am Mateon Therapeutics presents data from its on-going phase 1b OX1222 study of OXi4503 in combination with cytarabine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome at ASH 2016
us.rd.yahoo.com - December 6 at 10:01 AM
biz.yahoo.com logoMATEON THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events
biz.yahoo.com - November 23 at 9:08 AM
biz.yahoo.com logoMATEON THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
biz.yahoo.com - October 28 at 9:40 AM

Social

Chart

Mateon Therapeutics (MATN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.